Roche said it would pay $7.1 billion up front and a near-term milestone payment of $150 million. Under the agreement, the company will gain the rights to develop, manufacture and commercialize Telavant’s RVT-3101 drug candidate for inflammatory bowel disease.
Three more things to note:
- According to The Wall Street Journal, Roivant and Pfizer formed Telavant last year to develop and commercialize the drug candidate, with Roivant owning 75% and Pfizer 25%. Roivant was founded in 2014 by Republican presidential candidate Vivek Ramaswamy.
- RVT-3101 demonstrated meaningful efficacy and a favorable safety profile in treating ulcerative colitis in phase 2 trial results reported early this year. Once the Roche deal closes, the company will work quickly to move the drug into phase 3 trials, it said in its agreement announcement.
- Pfizer will hold commercialization rights to the drug outside of the U.S. and Japan. Once the deal closes, Roche will also have the option to enter a global collaboration with Pfizer on a next-generation antibody for inflammatory bowel disease, p40/TL1A, currently in phase 1 trials.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
